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Abstract 
Background: The increasing incidence of radiation‑induced osteosarcoma of the maxilla and mandible (RIOSM) has 
become a significant problem that can limit long‑term survival. The purpose of this study was to analyze the associa‑
tion of clinicopathologic characteristics with treatment outcomes and prognostic factors of patients who developed 
RIOSM after undergoing radiotherapy for nasopharyngeal carcinoma (NPC).
Methods: We reviewed the medical records of 53,760 NPC patients admitted to Sun Yat‑sen University Cancer Center 
during the period August 1964 to August 2012. Of these patients, 47 who developed RISOM and met inclusion criteria 
were included in this study. Two of these 47 patients refused treatment and were then excluded.
Results: For all patients treated for NPC at Sun Yat‑sen University Cancer Center during the study period, the total 
incidence of RIOSM after radiotherapy was 0.084% (47/53,760). Two patients (4.4%) had metastases at the diagnosis of 
RIOSM. Thirty‑nine of the 45 (86.7%) patients underwent surgery for RIOSM; most patients (24/39; 61.5%) who under‑
went resection had gross clear margins, with 15 patients (38.5%) having either a gross or microscopic positive margin. 
All patients died. The 1‑, 2‑, and 3‑year overall survival (OS) rates for the entire cohort of 45 patients were 53.3%, 35.6% 
and 13.5%, respectively. The independent prognostic factors associated with high OS rate were tumor size and treat‑
ment type.
Conclusions: RISOM after radiotherapy for NPC is aggressive and often eludes early detection and timely inter‑
vention. Surgery combined with postoperative chemotherapy might be an effective treatment to improve patient 
survival.
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Background
Most osteosarcomas arise in normal bone spontane-
ously, but it has been reported that approximately 5.5% 
of all osteosarcomas are caused by radiation exposure 
[1]. Radiation-induced osteosarcoma (RIOS) is a rare and 
potential late complication of radiotherapy for diseases 
including Hodgkin’s disease, retinoblastoma, breast can-
cer, and pelvic cancer.
Nasopharyngeal carcinoma (NPC) has a distinct geo-
graphic distribution: the incidence is generally less than 
1 per 100,000 person-year in most areas of the world, but 
the incidence is as high as 20–50 per 100,000 person-
years in southern China and southeastern Asia [1–4]. 
The most effective treatment for NPC is radiotherapy 
[5]. Unfortunately, radiotherapy can cause serious com-
plications, and the risk of late complications in irradiated 
tissues must be considered when radiotherapy is pre-
scribed with curative intent. The target volumes in NPC 
include the skull base, as well as the maxilla, mandible, 
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and pterygoid bone, and RIOS may arise in these sites as 
a late complication of radiotherapy.
RIOS of the maxilla and mandible (RIOSM) is an 
uncommon, aggressive tumor that occurs 5 years or more 
after radiotherapy [1, 5]. Management of RISOM is chal-
lenging, and little has been reported in the English-lan-
guage literature about the characteristics and prognosis 
of RIOSM after radiotherapy for NPC. The purpose of 
this study was to analyze the association of clinicopatho-
logic characteristics with treatment outcomes and prog-
nostic factors of patients who developed RIOSM after 
undergoing radiotherapy for NPC.
Patients and methods
Patient selection
We reviewed the medical records of 53,760 NPC patients 
admitted to Sun Yat-sen University Cancer Center in 
Guangzhou, Guangdong, China, between August 1964 
and August 2012 and identified 1074 cases of bone sar-
coma. Based on the criteria for radiation-induced sar-
coma published by Cahan et  al. [6], we selected the 
patients who met the diagnostic guidelines for RIOSM 
as follows: (1) the neoplasm originated in the irradiated 
field; (2) the initial bone condition was non-malignant in 
nature (this criterion was subsequently modified by Arlen 
et al. [7] to “tumors developed in bone not known to have 
a primary malignant osteoplastic lesion when the radio-
therapy was given”); (3) the neoplasm was histologically 
diagnosed as osteosarcoma; and (4) there was a relatively 
long latency period.
Follow‑up and statistical analysis
The latency period was defined as from the date of the 
first irradiation treatment of NPC to the date of patho-
logic diagnosis of RIOSM [6]. Follow-up duration was 
calculated from the date of diagnosis of RIOSM to the 
date of last follow-up. The cutoff time was the date of the 
last contact of these patients or the date of last follow-
up. The occurrence rate of RIOSM in patients with NPC 
treated with radiotherapy was calculated by analyzing 
the medical records of all patients with NPC treated at 
Sun Yat-sen University Cancer Center during the study 
period.
The following variables were analyzed with respect to 
survival: (1) patient factors: age and sex; (2) treatment 
of NPC: irradiation course and radiation dose (Gy); (3) 
RIOSM tumor factors: TNM stage, tumor site, and tumor 
size; (4) RIOSM pathologic factors: status of surgical 
margins; and (5) treatment of RIOSM: surgery, radiother-
apy, chemotherapy, or a combination of these strategies.
Overall survival (OS) was calculated from the date 
of RIOSM diagnosis to the date of either death or 
the last follow-up. OS rates were estimated using the 
Kaplan–Meier method and compared using the log-rank 
test. All statistical analyses were performed using SPSS 
version 22.0 software (SPSS Inc., Chicago, IL, USA). 
P values less than 0.05 were considered statistically 
significant.
Results
Characteristics of patients with RIOSM after radiotherapy 
for NPC
Forty-seven patients who developed RIOSM after radio-
therapy for NPC were eligible for this study; however, 
two patients who had major complications and refused 
treatment or were managed conservatively were there-
fore excluded from the study. For all patients treated for 
NPC at our hospital during the study period, the total 
occurrence rate of RIOSM after radiotherapy for NPC 
was 0.084% (47/53,760). The clinicopathologic character-
istics of all 45 included patients (33 men and 12 women) 
who were diagnosed with RIOSM after radiotherapy for 
NPC are listed in Table  1. When the patients first pre-
sented with NPC, they aged from 13 to 64 years (median 
38  years); at diagnosis of RIOSM, they aged from 18 
to 69  years (median 49  years). Of the 45 patients with 
RIOSM, 22 (48.9%) had a tumor ≤5 cm in diameter, and 
23 (51.1%) had a tumor >5 cm; 33 (73.3%) arose RIOSM 
in the maxilla, and 12 (26.7%) in the mandible. Two 
patients (4.4%) had metastases at diagnosis of RIOSM. 
Thirty-nine of the 45 patients (86.7%) underwent surgery 
for RIOSM; of the 39 patients, 24 (61.5%) who underwent 
resection had gross clear margins, and 15 (38.5%) had 
either a gross or microscopic positive margin.
Latency between radiotherapy for NPC and RIOSM
The median latency period was 8.0  years (range 3.0–
34.0 years). RIOSM developed within 5 years after radio-
therapy in 6 patients (13.3%); in 13 patients (28.9%), the 
latency was >10 years. The latency to RIOSM was signifi-
cantly shorter for patients who received a radiation dose 
>68  Gy than for those who received ≤68  Gy (median 
13.6 vs. 8.0  years, P  =  0.005). The latency was not sig-
nificantly different among the groups of patients who 
received orthovoltage, cobalt-60, or megavoltage X-rays 
(P  =  0.569), between men and women (P  =  0.464), or 
between patients aged ≤38 and >38 years (P = 0.848).
Treatment of RIOSM
Of the 45 patients, 6 (13.3%) who either had non-
resectable lesions or rejected surgery received chemo-
therapy alone; 39 (86.7%) underwent surgery, including 
30 (66.7%) who underwent surgery only, 8 (17.8%) who 
underwent surgery and also received chemotherapy, 
and 1 (2.2%) who received surgery, chemotherapy, and 
radiotherapy. After extensive resection, two patients 
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underwent reconstruction with a free anterolateral fem-
oral skin flap, and two patients underwent regional flap 
reconstruction, including a temporalis muscle flap and 
a pectoralis major myocutaneous flap. All reconstruc-
tions were successful. Of the 39 patients undergoing 
radical excision, 24 (61.5%) achieved gross negative mar-
gins, and 15 (38.5%) had gross or microscopic positive 
margins. Eight patients, including one who underwent 
complete resection and seven who underwent incom-
plete resection, received postoperative chemotherapy on 
an individualized basis. One patient underwent surgery 
with incomplete resection; this patient received chemo-
therapy plus radiotherapy (median dose, 60 Gy). For this 
retrospective study, detailed records of the chemotherapy 
drugs were not available.
Follow‑up and outcome
For the censored data analysis, the cutoff date for last 
follow-up was August 31, 2014. The mean follow-up 
duration was 17.9  months (range 2.1–56.5  months). 
All patients died before the last follow-up; the 1-, 2-, 
and 3-year OS rates for the entire cohort of 45 patients 
were 53.3%, 35.6% and 13.5%, respectively (Fig.  1a). Of 
the 39 patients who underwent surgery for RIOSM, 
10 developed tumor recurrence and all died of disease 
within 1–10  months after diagnosis of tumor recur-
rence (median 8.0 months). The interval between surgery 
and tumor recurrence ranged from 5.0 to 65.5  months 
(median 16.9 months). Of the patients who experienced 
tumor recurrence, 6 (60.0%) recurred in the first year, 
3 (30.0%) recurred in the second year, and 1 (10.0%) 
recurred in the third year; 2 (20.0%) had received sur-
gery, 4 (40.0%) had received palliative chemotherapy, 
and 4 (40.0%) had received conservative therapy. The two 
patients with RIOSM who were excluded from the study 
because of treatment refusal both died within 2 months 
of diagnosis of RIOSM.
Prognostic factors for OS of patients with RIOSM
The univariate analysis results showed that RIOSM 
tumor size and treatment type were prognostic factors 
for OS (Table 2). The 1- and 2-year OS rates were 81.8% 
and 59.1%, respectively, for patients with tumors ≤5 cm 
and were 26.1% and 13.0%, respectively, for patients with 
tumors >5  cm (P =  0.007; Fig.  1b). In this cohort, only 
one patient received a combination of surgery, chemo-
therapy, and radiotherapy. Therefore, to analyze the effect 
of treatment, we stratified the remaining 44 patients into 
three groups: surgery alone (30 patients), chemotherapy 
alone (6 patients), and combined surgery and chemo-
therapy (8 patients). Median OS was 14.4 months for the 
surgery-alone group, 9.0  months for the chemotherapy-
alone group, and 33.6 months for the combined surgery 
and chemotherapy group. The 1- and 2-year actuarial OS 
rates for the surgery-alone group were 53.3% and 36.7%, 
respectively, compared with 33.3% and 0.0%, respectively, 
for the chemotherapy-alone group and 75.0% and 62.5%, 
respectively, for the combined surgery and chemother-
apy group (P = 0.013; Fig. 1c). Using the average values 
as cutoff points, patient age, radiation dose, and latency 
were not significant prognostic factors for OS. Moreo-
ver, the univariate analysis results showed that sex, TMN 
stage, irradiation source and recurrence were also not 
significantly associated with OS (Table  2). Surprisingly, 
in multivariate analysis, margin status was not a signifi-
cant prognostic factor. We performed additional analy-
sis of OS based on the margin status in the 39 patients 
who received surgery alone. The 1- and 2-year actuarial 
OS rates for the 19 patients with negative margins were 
63.1% and 47.0%, respectively, versus 40.2% and 20.1%, 
respectively, for the 10 patients with positive margins 
(P = 0.029 for 1-year OS rates and P = 0.023 for 2-year 
OS rates).
Discussion
Although radiotherapy is an effective treatment of NPC, 
it also has the potential to cause secondary malignancies. 
The incidence of RIOSM is on the rise due to improved 
Table 1 The clinicopathologic characteristics of  45 
patients who were diagnosed with  radiation-induced 
osteosarcoma of  the maxilla and  mandible (RIOSM) 
after  undergoing radiotherapy for  nasopharyngeal carci-
noma
a Only 39 of 45 patients underwent surgery
Characteristic No. of patients (%)
Sex
 Men 33 (73.3)
 Women 12 (26.7)
Age (years)
 ≤49 21 (46.7)
 >49 24 (53.3)
Tumor size (cm)
 ≤5 22 (48.9)
 >5 23 (51.1)
Tumor site
 Maxilla 33 (73.3)
 Mandible 12 (26.7)
Latency period (years)
 ≤8.0 23 (51.1)
 >8.0 22 (48.9)
Margin statusa
 Negative 24 (61.5)
 Positive 15 (38.5)
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early discovery and treatments of NPC [1–3]. In the Eng-
lish-language literature, one study reported a cumulative 
occurrence rate of 0.03%–0.8% of RIOSM after radiother-
apy in patients with NPC [2]. Liu et al. [1] estimated that 
the occurrence rate of RIOSM in patients with NPC was 
nearly 0.037%; of the 15 cases they studied, five tumors 
arose in the maxilla, seven in the mandible, and three in 
the junction of the nasal cavity and para-nasal sinuses. In 
our study, we considered RIOSM arising in the maxilla 
(33 cases) and mandible (12 cases) only, with a maxilla-
versus-mandible ratio of 2.75:1, corresponding to an esti-
mated cumulative occurrence rate of 0.084%.
Radiotherapy is the most common treatment of NPC, 
and the irradiation fields may extend from the skull base 
down to the lower neck region. As a late complication of 
radiotherapy, osteosarcoma can arise in the maxilla and 
mandible. Some researchers have suggested that RIOSM 
is most likely to occur after exposure to doses <30  Gy 
[6, 7]. In our study, the mean dose that patients received 
was 68 Gy, which was much higher than the mean dose 
of 45 Gy (range 25–110 Gy) that was reported in a pre-
vious study of RIOS [8]. Since the maxilla and mandible 
were not as routine conservation tissue it is difficult to 
calculate the exact radiation dose on the bones in NPC 
radiotherapy. Moreover, many uncertainties can affect 
the calculation of radiation dose, such as scatter dose; a 
previous study pointed out that a high scatter dose would 
cause scattering low dose ratio, which induced malignan-
cies [9]. As radiotherapy technology advances, ionizing 
radiation dose may affect the occurrence rate of RIOSM. 
However, we could not obtain exact data on the radiation 
dose that would increase the occurrence rate of second-
ary malignancies.
Intensity-modulated radiotherapy (IMRT) has enabled 
target volumes to be more precisely, but IMRT actu-
ally increases the volume of normal tissue subjected 
to low-dose ionizing radiation [10]. Some researchers 
Fig. 1 Overall survival (OS) curve for 45 patients with radiation‑induced osteosarcoma of the maxilla and mandible (RIOSM). a OS curve for 45 
patients with RIOSM who underwent radiotherapy for nasopharyngeal carcinoma. b OS for two groups stratified by different diameter. c OS for 
three groups stratified by different treatments
Table 2 Association of overall survival with the character-
istics of 45 patients with RIOSM
a Three patients did not have available information
Characteristic No. of patients Survival rate (%) P
1‑year 2‑year
Age (years)
 ≤49 21 52.4 42.9 0.676
 >49 24 54.2 29.2
Sex
 Women 12 41.7 33.3 0.572
 Men 33 57.6 36.4
Size (cm)
 ≤5 22 81.8 59.1 0.007
 >5 23 26.1 13.0
TNM stage
 I/II 19 52.6 36.8 0.159
 III/IV 26 53.8 34.6
Irradiation coursea
 Split 15 46.7 33.3 0.721
 Continuous 27 55.6 37.0
Radiation dose (Gy)
 ≤68 22 59.1 45.5 0.129
 >68 23 47.8 26.1
Latency period (years)
 ≤8.0 23 60.9 39.1 0.699
 >8.0 22 40.9 31.8
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have suggested that medium-to-low-dose radiation may 
induce carcinogenesis more effectively than high-dose 
radiation [5, 10]. Moreover, some studies have found 
that concurrent chemotherapy significantly improved 
treatment outcomes in NPC patients, although oth-
ers have suggested that chemotherapy may increase the 
risk of radiation-induced sarcoma [11, 12]. We made 
two speculations: first, whether IMRT indeed increases 
the occurrence rate of secondary malignancies; and sec-
ond, whether IMRT did not increase the risk of second-
ary cancer. These speculations should be tested in future 
studies with a longer follow-up and a larger number of 
patients by analyzing clinicopathologic data. As more 
patients with NPC are treated with irradiation and 
now survive longer, the incidence of RIOSM is likely to 
increase [13, 14].
Previous studies reported latencies ranging from 5.0 to 
30.0  years (mean 12.9  years) [15]. Similarly, in the pre-
sent retrospective study, the median latency of RIOSM 
was 8.0  years (range 3.0–34.0  years). The factors that 
influence latency are unknown. In this cohort, patients 
who received radiation doses >68 Gy had a significantly 
shorter latency than patients who received ≤68  Gy 
(P = 0.005). However, the radiation source (orthovoltage, 
cobalt-60, or megavoltage X-rays) and patient sex or age 
had no significant effect on latency.
RIOSM is an aggressive tumor with a very poor prog-
nosis. Most studies have reported low 5-year OS rates, 
ranging from 10% to 30% [16–21]. In the most recent 
study reported by Tabone et al. [22], the 8-year OS and 
disease-free survival rates for 23 patients with RIOSM 
were 50% and 41%, respectively, suggesting that the 
prognosis of patients with RIOSM has improved over 
time. However, in our cohort, the 1-, 2-, and 3-year 
actuarial OS rates for patients with RIOSM were 53.3%, 
35.6% and 13.5%, respectively. Moreover, all patients 
died within 5 years after RIOSM diagnosis. Other stud-
ies have reported that the 5-year OS rate of patients 
with primary maxillofacial osteosarcoma was 44%–70% 
[6, 7, 13, 23, 24]. RISOM results in worse outcomes 
compared with stage-matched osteogenic sarcomas 
of the jaw. Thiagarajan et  al. [25] suggested that the 
poor outcomes were due to the following reasons: (1) 
delayed diagnosis in previously irradiated tissue; (2) 
compromised resection margins, due to proximity of 
the tumor to critical structures; (3) limited treatment 
options in a maximally irradiated field (i.e., technical 
difficulties of operating within an irradiated field and 
difficulties with irradiation to the field with surround-
ing normal tissues, which have been treated to near 
tolerance); (4) poor tumor sensitivity to chemotherapy; 
(5) the high-grade nature of the vast majority of RIOS; 
and (6) host immunosuppression caused by a combina-
tion of tumor-related factors and previous treatment 
[1, 26, 27]. This study clearly indicates that the progno-
sis of patients with RIOS in the maxilla and mandible is 
poorer than patients with primary osteosarcoma of the 
maxilla and mandible.
The incidence of radiation-induced sarcoma of head 
and neck (RISHN) is increasing, with an estimated risk 
of up to 0.3% [2, 23]. RISHN development may be influ-
enced by radiation dose, age at initial exposure, exposure 
to chemotherapeutic agents, and genetic features. RISHN 
is associated with poor outcomes, and surgical resection 
with clear margins seems to offer the best chance for cure 
[23]. Management of RISOM is more challenging, entail-
ing surgery for irradiated tissue and a limited scope for 
further radiotherapy and chemotherapy.
Treatment for RIOSM includes surgery, radiotherapy, 
chemotherapy, or a combination of these strategies. 
Complete surgical excision seems to be necessary for 
the treatment of radiation-induced sarcoma; however, in 
patients with RIOSM, radical surgery is suitable only for 
early-stage tumors [1]. Although preoperative assessment 
can help determine the surgical boundaries, it is difficult 
for surgeons to judge whether the tumor has already 
invaded to the surrounding area. Moreover, RIOSM 
often occurs close to important structures such as the 
carotid artery and skull base; radical surgery in these 
regions is associated with a high risk of critical damage 
to important structures. The significance of chemother-
apy for RIOSM is under debate: some researchers have 
concluded that RIOSM is insensitive to chemotherapy, 
whereas others have stated that chemotherapy is effec-
tive [1, 25, 28]. One study reported that a combination of 
surgery and chemotherapy resulted in a higher OS rate 
than either surgery alone or chemotherapy alone [29]. In 
our cohort, 39 patients underwent surgery; of these 39 
patients, 15 (38.5%) had gross or microscopic positive 
margins. In multivariate analysis, margin status was not 
significantly associated with OS. However, for patients 
who received surgery alone, a negative margin was asso-
ciated with significantly higher 1- and 2-year OS rates 
(19 patients; 63.1% and 47.0%, respectively) than a posi-
tive margin (10 patients; 40.2% and 20.1%, respectively; 
P  =  0.029, P  =  0.018). We suggest that radical surgery 
with a negative margin leads to a significantly better 
prognosis for patients with RIOSM. In our cohort, chem-
otherapy alone did not influence survival. Therefore, sur-
gery combined with postoperative chemotherapy may be 
an effective strategy to improve survival for patients with 
RIOSM. In our cohort, since only one patient received 
combined surgery, chemotherapy, and radiotherapy, 
we cannot make any definitive conclusions about the 
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effectiveness of combined treatment for RIOSM. In fact, 
it has been reported that radiotherapy provides no sur-
vival benefit for patients with RIOSM [18, 21, 30–32].
In our cohort, RIOSM tumor size had prognostic sig-
nificance. In agreement with the results of other stud-
ies [3, 23–27], we found that a larger tumor was more 
likely to be associated with more advanced disease and 
resulted in a poorer treatment outcome. Furthermore, in 
cases with large tumors surrounded by vital tissues, it is 
extremely risky and difficult to perform radical surgery 
and achieve a negative margin.
Unlike other reports [7, 21, 33], in our study recur-
rence was not prognostic for disease control status. 
RIOSM is an aggressive sarcoma, and, in our study, the 
mean OS time was 14.2  months, and only 20 patients 
survived for more than 16 months. However, the interval 
between surgery and tumor recurrence ranged from 5.0 
to 65.5 months (mean 16.9 months). We contend that all 
of the deaths in our study were due to RIOSM. However, 
only a small proportion of RIOSM cases in our study 
could be detected on clinical examination and received 
appropriate treatment.
The potential limitations of our study are its retro-
spective nature, the relatively small sample size, and the 
fact that it was performed at a single institution. Given 
the rarity of this complication, larger multi-center pro-
spective studies should be conducted to confirm these 
preliminary results and further analyze the treatment 
outcomes.
Conclusions
Our study confirmed the low occurrence rate and poor 
prognosis of RIOSM in patients with NPC. Complete 
surgical resection was a significant prognostic factor for 
survival. Surgery combined with postoperative chemo-
therapy may be an effective strategy to improve survival 
for patients with RIOSM. We concluded that long-term 
follow-up is necessary for the early detection of RIOSM 
in patients with NPC.
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